Research Information System
Bratislava Medical Journal, vol.126, no.10, pp.2658-2673, 2025 (SCI-Expanded, Scopus)
Background: This study investigates the effects of carbamazepine (CBZ) carbon nanodot functionalized silver nanoparticles (CBZ-CD@AgNP) and carbamazepine-loaded metal–organic frameworks (CBZ-CDs@MOFs) on the brain of male rats in an epilepsy model. Methods: In our study, 70 male Wistar albino rats aged 8–12 weeks were used. Experimental groups Control group, PTZ (Pentylenetetrazole) group, Carbamazepine 25 mg/kg group, Carbamazepine 50 mg/kg group, PTZ + Carbamazepine 25 mg/kg group, PTZ + Carbamazepine 50 mg/kg group, Carbamazepine 25 mg/kg + MOF group, Carbamazepine 50 mg/kg group + MOF group, PTZ + Carbamazepine 25 mg/kg group + MOF group, PTZ + Carbamazepine 50 mg/kg group + MOF group. Results: Immunohistochemical analysis showed an increase in GRP78 expression in all CBZ-nanoparticle groups, indicating a protective effect. However, 25 mg/kg doses of both nanoparticles in PTZ-treated animals elevated TNF-α expression, suggesting a possible negative dose-dependent effect. TAS levels were significantly increased in the PTZ + CBZ-CDs@MOFs 25 mg/kg and 50 mg/kg groups, implying an antioxidant role for MOF particles. No significant changes were observed in TOS and MDA levels. Conclusions: This research underscores the therapeutic promise of nanomaterials in epilepsy management, paving the way for advanced treatments.